Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lymphatic Malformation
- Main trialPhase 1
- “The primary objective of this study is to evaluate the safety and tolerability of CERC-006 in adults (aged 18-31 years) with active, moderate to severe complex lymphatic malformations.”In the company’s words, NCT04994002 on ClinicalTrials.gov
Other drugs for Lymphatic Malformation
- KP-001Kaken Pharmaceutical · Phase 3
- AlpelisibNovartis · Phase 2/3
- QTORIN 3.9% rapamycin anhydrous gelPalvella Therapeutics, Inc. · Phase 3
- TARA-002Protara Therapeutics · Phase 2
- ZovegalisibRelay Therapeutics, Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Withdrawn | Jun 2022 | A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026